Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important

Principles 

By using the website www.bellevue.ch, you confirm that you have read, understood and accepted the general information provided by the Bellevue Group AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Target group of the sites 

The sites are intended exclusively for use by legal entities and natural persons having their registered office or residing in countries in which the investment funds or the related subfunds or share classes of the Bellevue Group have been properly licensed or approved for public offer or sale in accordance with the applicable local legislation. The funds are currently registered for public distribution offer in the following countries: Luxembourg, Switzerland, Germany, Austria, Spain and Portugal. In all other countries, the funds may, if any, via "Private Placement" according to the local applicable laws.

It is explicitly stated, that alternative fund products are not allowed for public distribution in any country and that they may only and exclusively be solicited to institutional and qualified private investors according to the applicable local laws of each country.

The information and services provided on the sites are not intended for offer to or use by legal entities or natural persons in legal jurisdictions or countries in which the offer or use thereof would violate local legislation or legal provisions, or in which business units forming part of Bellevue Group would be subject to registration requirements in such jurisdictions or countries. Legal entities or natural persons to which such prohibitions apply must not access or use these sites.

The Bellevue funds have NOT been licensed for public offer or sale to the public in the United States in accordance with the US Investment Company Act of 1940 or the US Securities Act of 1933, or in Canada, Japan, Taiwan, Malaysia, Hong Kong or Israel in accordance with the laws in force in those countries. Therefore, particular importance is attached to ensuring that these sites are not intended for legal entities or natural persons, who have their registered office or who reside in such countries, their territories or dependencies or who, on account of their citizenship or similar status, are subject to the law of one of these countries.

Fund documents Luxembourg Fund

Bellevue SICAV: The Bellevue Funds (Lux) SICAV is admitted for public offering and distribution in Switzerland . Representative agent in Switzerland   Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne and paying agent in Switzerland: DZ PRIVATBANK (Schweiz) AG Münsterhof 12, PO Box, CH-8022 Zürich. Austria: Paying and information agent: Zeidler Legal Process Outsourcing Limited., 19-22 Lower Baggot Street, Dublin 2, D02 X658, Ireland. Germany: information agent: Zeidler Legal Process Outsourcing Limited., 19-22 Lower Baggot Street, Dublin 2, D02 X658, Ireland. Spain: The Bellevue Funds (Lux) SICAV is registered with the CNMV under the number 938. Paying and information agent: atl Capital, Calle de Montalbán 9, ES-28014 Madrid.  Prospectus, Key Investor Information Document (“KID”), the articles of association as well as the annual and semi - annual reports of the Bellevue Funds under Luxembourg law are available free of charge from the above mentioned representative, paying, facilities and information agents as well as from Bellevue Asset Management AG, Seestrasse 16 , CH - 8700 Kusnacht. 

Bellevue Asset Management (Deutschland) GmbH: You can obtain the sales prospectus, the annual reports and the german key investor information documents free of charge from Bellevue Asset Management (Deutschland) GmbH, and also from banks and financial advisers. Paying agent in Switzerland is DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, PO Box, CH-8022 Zurich. The swiss agent is IPConcept (Schweiz) AG, In Gassen 6, PO Box, CH-8022 Zurich. In Switzerland you can obtain sales prospectus, the annual reports and the german key investor information documents free of charge from the agent and also from the paying agent. 

Fund documents Bellevue Entrepreneur Switzerland

Prospectus, Key Investor Information Document („KID“), fund contract as well as the annual and semi - annual reports of the Bellevue Fund under Swiss law are available free of charge from: Switzerland : PMG Fonds Management AG, Dammstrasse 23, 6300 Zug or Bellevue Asset Management AG, Seestrasse 16, CH - 8700 Kusnacht. 

Fund documents Bellevue Funds and Bellevue Healthcare Strategy

Prospectus, Key Investor Information Document („KID“), fund contract as well as the annual and semi - annual reports of the Bellevue Medtech and Services fund established under Swiss law in the category "Other Funds for Traditional Investments" are available free of charge from : Switzerland : Swisscanto Fondsleitung AG, Bahnhofstrasse 9 , CH - 8001 Zürich or Bellevue Asset Management AG, Seestrasse 16 , CH - 8700 Kusnacht

Fund documents StarCapital Equity Value plus, StarCapital Multi Income, StarCapital Strategy 1 and StarCapital Dynamic Bonds.

Prospectus, the key investor information document ("KID"), the management regulations and the semi-annual and annual report are available free of charge in German from Bellevue Asset Management (Deutschland) GmbH, your advisor or intermediary, the paying agents, the relevant custodian bank or from the management company IPConcept (Luxembourg) S.A. (société anonyme), 4, rue Thomas Edison, L-1445 Luxembourg, Luxembourg, https://www.ipconcept.com. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.ipconcept.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

Fund documents Bellevue Option Premium fund

Prospectus, the key investor information document ("KID"), the management regulations and the semi-annual and annual reports are available free of charge in German from Bellevue Asset Management (Deutschland) GmbH, your advisor or intermediary, the paying agents, the responsible depositary (UBS Europe SE, Bockenheimer Landstrasse 2-4, D-60306 Frankfurt am Main) or from the management company Universal-Investment-Gesellschaft mbH, Theodor-Heuss-Allee 70, D-60486 Frankfurt am Main, https://www.universal-investment.com. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.universal-investment.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

 Fund documents StarCapital Premium Bonds plus  

Prospectus, the key investor information document ("KID"), the management regulations and the semi-annual and annual reports. These can be obtained free of charge in German from Bellevue Asset Management (Deutschland) GmbH, your advisor or intermediary, the paying agents, the responsible depositary (UBS Europe SE, Bockenheimer Landstrasse 2-4, D-60306 Frankfurt am Main) or from the management company Donner & Reuschel AG, Ballindamm 27, 20095 Hamburg, https://www.donner-reuschel.de. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.universal-investment.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions. 

Artificial intelligence is transforming the healthcare industry – although for now the mega caps are the ones benefiting the most from its deployment. These giant companies have the resources, the data, and the know-how to reap the biggest and best rewards that this technological revolution is bringing. Exactly how much potential does AI offer for the healthcare sector and what opportunities do the smaller players have?

The big fish in the ocean of data: Why AI in healthcare favors the biggest players

Artificial intelligence is transforming the healthcare industry – although for now the mega caps are the ones benefiting the most from its deployment. These giant companies have the resources, the data, and the know-how to reap the biggest and best rewards that this technological revolution is bringing. Exactly how much potential does AI offer for the healthcare sector and what opportunities do the smaller players have?
08.11.2024 - Marcel Fritsch

The power of deep pools of data
The healthcare sector has a tremendous advantage when it comes to the use of artificial intelligence (AI): It has huge amounts of data and this data is essential when it comes to developing innovative AI-powered applications. As AI becomes increasingly anchored across the healthcare sector, major pharmaceutical and biotechnology companies such as Eli Lilly, Novo Nordisk and Amgen are attracting growing attention. AI-driven value added is currently heavily concentrated in mega and large caps, as these are the companies that already have the financial wherewithal and the vast datasets that are needed to actively pursue AI projects. By collaborating with tech giants such as Microsoft and Nvidia, healthcare companies are growing their AI capabilities and significantly shortening R&D cycles. These alliances spell new opportunities for personalized medicine and robot-assisted solutions – areas where smaller players are struggling to gain traction.

Artificial intelligence – an exclusive driver of competitive advantage
The dominance of American companies in the Bellevue AI Health Fund's portfolio can, to some extent, be traced to developments in the field of artificial intelligence, developments that reflect that country's tremendous capex power and AI-friendly infrastructure.

The US invests six times as much capital in medical research than the three largest European countries. Most of the major providers of AI technology – Nvidia, Microsoft, and Qualcomm, to name a few – are also based in the US, which facilitates collaboration and spurs further innovation.

Companies such as Roche and Novartis have demonstrated that European companies can nevertheless compete in the field of AI. Genentech (Roche), in collaboration with Nvidia, is relying on generative artificial intelligence (GenAI) to speed up diagnostics processes and the development of treatment solutions, while Novartis launched its AI Innovation Lab back in 2019. Novartis's goal here is to make CAR-T cell therapies for cancer immunotherapy even more precise and to customize treatments even better for each individual patient.

Emerging markets out of the picture – for now
The prospects of AI investments in emerging markets is an interesting question. Although India, Brazil and parts of Africa boast considerable IT expertise, there are hardly any companies from these countries in the portfolio of the Bellevue AI Health Fund. This can be traced to their low stock-market capitalizations and low rankings in the Bellevue AI Affinity Score, which serves as a valuation yardstick for the fund's investment activities. One exception is QuantumPharm, a company based in Shenzhen that specializes in AI and robotics for drug discovery and development and that we consider a promising pioneer, which is why it is in the fund's portfolio.

Emerging markets could, however, play a more important role at some point in the future, especially if the current high barriers to entry are reduced in the wake of declining technology costs. This could give small and mid-sized businesses better access to the necessary data and AI technology, and thus enable their greater participation in AI-driven healthcare market developments.

AI developments in niche markets
In the mid-cap segment, these two companies are interesting: Procept BioRobotics has taken a decisive position with its Hydros Robotic System for the resection of prostate tissue. Hydros is an AI-powered platform that surgeons use to map treatment planning, which is then carried out with single-use disposable handpieces, resulting in faster, safer, and more consistent treatment results regardless of surgeon experience. With nearly 450 robotic systems already installed, Hydros is in an excellent position to gain wide market acceptance thanks to the system's high degree of integration and simplified workflows. Dexcom has launched an innovative new product that enables it to target a new customer segment in the field of diabetes. With its recently approved Stelo glucose sensor, the company now offers a "wearable" solution for diabetics who are not on insulin. This sensor helps users to better understand the relationship between diet, exercise, and blood sugar levels. Stelo expands Dexcom’s product portfolio beyond the insulin-dependent patient segment and broadens the company’s target market.

Conclusion: Everything the same as before – or is it?
It is hard to think of an industry that is more suited or attractive for the deployment of artificial intelligence than healthcare. The copious amounts of data that are generated across the healthcare system day after day provide almost unlimited opportunities for personalized diagnostics, precision therapeutics, or more efficient clinical trials, for example. Large pharmaceutical and biotechnology companies can make the most of this big data thanks to their vast resources and experience in handling sensitive patient health information. AI helps them to identify complex patterns in large health datasets and thereby significantly increase the efficiency of their research and development activities. Examples of the revolutionary developments this has enabled are AI-powered analysis of medical images and identification of active ingredients for drug formulations.

While it may be challenging for smaller players to adapt to these new dynamics, they do offer them opportunities too – for example through collaborative arrangements and specialized niche applications that enable them to leverage the potential of AI without owning their own big data or having extensive resources at their disposal.

These investment strategies might interest you